SEC 13F Intelligence

Deep Track Capital, LP / TCE2

Deep Track Capital, LP’s Celldex Therapeutics Inc New Position

Does Deep Track Capital, LP own Celldex Therapeutics Inc New (TCE2)? Yes — 1.28M shares worth $41M (+0.67% of its 13F portfolio) as of Q1 2026, down from 1.90M shares the prior filed quarter.

Position Value
$41M
Q1 2026
Shares
1.28M
% of Portfolio
+0.67%
Quarters Held
6
currently held

Position History TCE2

Reported value by quarter
Q4 ’24: $39MQ4 ’24Q1 ’25: $36MQ1 ’25Q2 ’25: $41MQ2 ’25Q3 ’25: $52MQ3 ’25Q4 ’25: $52MQ4 ’25Q1 ’26: $41MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.28M$41M+0.67%
Q4 20251.90M$52M+0.92%
Q3 20252.00M$52M+1.44%
Q2 20252.00M$41M+1.31%
Q1 20252.00M$36M+1.18%
Q4 20241.54M$39M+1.45%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Deep Track Capital, LP’s full portfolio or all institutional holders of TCE2.